ClinicalTrials.gov
public full text
Public Domain
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML#1086817
- LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy#1171408
- Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result#863308
- Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients#840329
- Timed-Sequential Induction in CBF-AML#1095956
Record · ID 839290
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive